

(A joint stock limited

company incorporated



Contents

CONTENTS	2
FINANCIAL HISTORY	4
MANAGEMENT DISCUSSION AND ANALYSIS	5
CONTENTS OF THE ANNUAL REPORT	31
CONTENTS OF THE ANNUAL REPORT	41
CONTENTS OF THE ANNUAL REPORT	45
CONTENTS OF THE ANNUAL REPORT	49
CONTENTS OF THE ANNUAL REPORT	52
CONTENTS OF THE ANNUAL REPORT	54
CONTENTS OF THE ANNUAL REPORT	57
CONTENTS OF THE ANNUAL REPORT	59
CONTENTS OF THE ANNUAL REPORT	61
CONTENTS OF THE ANNUAL REPORT	63
DEFINITIONS	151



Corporate Information

B ● D₁ 監

Executive Directors

 .G. A. M. (C 1 1)
 . A. G. M.
 . A. G. J. M.




Non-executive Directors




 . I. H.
 . I. C. T.




Independent Non-executive Directors




 . H. G. T.
 . J. I. T.
 . C. H. A. (C 1 1)






A ● C 1 1



 . H. G. T. (C 1 1)
 . I. C. T.
 . J. I. T.



 . C. H. A. (C 1 1)
 . G. A. M.
 . J. I. T.

 . J. I. T. (C 1 1)
 . H. G. T.
 . C. H. A. (C 1 1)

 . G. A. M. (C 1 1)
 . H. G. T.
 . I. H.

 . I. C. T. (C 1 1)
 . Y. T. M.
 . H. A. G.
 . I. E. M.
 . I. A. C. T.

 . A. G. J. M.
 . G. A. M. (C 1 1)




 . G. A. M.
 . G. A. M. (C 1 1)

A ● 1

BD C 1 1 (C 1 1) ● A 1 1

 . A. G. J. M. (C 1 1)
 . H. G. T. (C 1 1)

 . H. G. T. (C 1 1)
 . I. C. T. (C 1 1)

 . H. G. T. (C 1 1)
 . I. C. T. (C 1 1)
 . J. I. T. (C 1 1)

Corporate Information

40/F, D
248
H
B

40/F, D
248
H
E

H

C
1712-1716, 17 F

H
133
H
E

C.

2120

C
H

H

F : (86) 577 3377 1639

F : (86) 577 3373 9117

E : info@h.com

合并现金流量表

合并现金流量表 E 续

	For the six months ended June 30,	
	2024 (RMB' 000) (Unaudited)	2023 (RMB' 000) (Unaudited)
经营活动产生的现金流量	828,957	777,925
投资活动产生的现金流量	61,513	60,207
筹资活动产生的现金流量	16,516	11,473
汇率变动对现金及现金等价物的影响	44,996	43,729
现金及现金等价物净增加额	50,724	43,750
期初现金及现金等价物余额	-5,727	4,979
期末现金及现金等价物余额	116,536	113,591

	As at	
	June 30, 2024 (RMB' 000) (Unaudited)	A June 30, 2023 (RMB' 000) (Unaudited)
货币资金	3,008,352	3,047,637
应收账款	1,581,890	1,639,431
预付款项	1,426,462	1,403,206
其他应收款	1,290,906	1,265,065
存货	135,555	143,141

Management Discussion and Analysis

B I E E I E A D

2024, G, C, F, G

...

2024, G, B329.0, 6.6%, B765.6, 5.1%, D, B50.7, 15.9%, A, J, 30, 2024, G, H, 31, 2023: 32), 11,643 (D, 31, 2023: 11,263).

Psychiatric Healthcare Business

G, G

...

Management Discussion and Analysis

於 2024, G 2,730 31.1% B23.1

G H C H A

y y H 2022, C H

G H 2022, C H

2021,


於 J 2024, G C D

H 2024 《深化醫藥衛生體制改革2024年重點工作任務》,

(固本革新,篤信行遠), Z

Z H G

Management Discussion and Analysis



Revenue and Cost of Revenue

Revenue and cost of revenue are presented in the following table. Revenue is presented in million RMB, and cost of revenue is presented in million RMB. Revenue and cost of revenue are presented in million RMB. Revenue and cost of revenue are presented in million RMB.

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Revenue	828,957	723,692
Cost of revenue	63,023	46,375
	298	2,353
Total revenue	828,957	777,925



Management Discussion and Analysis

0.000
 0.000
 0.000
 0.000

For the six months ended June 30,
 2024
 (RMB'000)
 (Unaudited)

2023
 (RMB'000)
 ()



Management Discussion and Analysis

Management Discussion and Analysis

For the six months ended June 30,
 2024 2023
 (Unaudited) (₹ million)

Inpatients

Number of inpatients	11,648	10,573
Estimated cost of inpatient services	2,119,936	1,914,613
Percentage of total revenue	87.4	84.0
Number of inpatient beds	1,852,397	1,607,422
Number of inpatient beds (B'000)	586,146	553,572

Management Discussion and Analysis

D 6.2% 15.2%, 2023, B677.2 G 15.2% (30, 2023: 35.7%).
 H 15.2%, 2023, B677.2 G 15.2% (30, 2023: 35.7%).
 H 15.2%, 2023, B677.2 G 15.2% (30, 2023: 35.7%).
 H 15.2%, 2023, B677.2 G 15.2% (30, 2023: 35.7%).

D 1.2% 4.2%, 2023, B107.7 G 13.7% (30, 2023: 14.3%).
 H 1.2% 4.2%, 2023, B107.7 G 13.7% (30, 2023: 14.3%).
 H 1.2% 4.2%, 2023, B107.7 G 13.7% (30, 2023: 14.3%).
 H 1.2% 4.2%, 2023, B107.7 G 13.7% (30, 2023: 14.3%).

D 5.2% 0.5 (0.5), 2023, B70 G 4.3% (30, 2023: 4.3%).
 H 5.2% 0.5 (0.5), 2023, B70 G 4.3% (30, 2023: 4.3%).
 H 5.2% 0.5 (0.5), 2023, B70 G 4.3% (30, 2023: 4.3%).
 H 5.2% 0.5 (0.5), 2023, B70 G 4.3% (30, 2023: 4.3%).

Management Discussion and Analysis

Gross Profit and Gross Profit Margin



For the six months ended June 30,
2024 2023
(Unaudited)

Management Discussion and Analysis

Administrative Expenses

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	()
E	64,383	55,922
D	13,955	13,474
C	4,042	14,377
	2,199	2,071
	21,692	16,080
Total administrative expenses	106,271	101,924

D 4.3% 15.1% 2023, 2023 2023. D 13.9% (30, 2023: 14.0%).

Management Discussion and Analysis

Finance Expenses – Net

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	()
Interest expense	-2,686	-2,705
Interest income	99	-13
Bank charges	18,078	14,124
Other finance expenses	5,245	5,058
Finance expenses – net	2,968	3,151
	761	545
Finance expenses – net	24,465	20,160

D 2023, B4.3 2023, B4.0 2023.

G 2023, B24.5 2023.

Management Discussion and Analysis

Investment Income/Loss

2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
投资收益 / 损失	479	-153
公允价值变动收益 / 损失	1,201	-33
	1,680	-196

D 2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月

Credit Impairment Losses

D 2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月
 2024 年 1-6 月 / 2023 年 1-6 月

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

Management Discussion and Analysis

Inventory

Inventory

A J 30, 2024, $\text{¥}51.9$ (D 31, 2023: $\text{¥}60.6$),
 A $\text{¥}8.7$ (D $\text{¥}9.3$)

Accounts Receivables

A J 30, 2024, $\text{¥}420.4$ (D 31, 2023: $\text{¥}443.1$),
 A $\text{¥}5.7$ (D $\text{¥}6.2$) 6.6%
 A $\text{¥}1.8$ (D $\text{¥}1.8$)

D $\text{¥}95.0$ (D $\text{¥}91.0$)

Other Receivables and Prepayments

A J 30, 2024, $\text{¥}72.3$ (D 31, 2023: $\text{¥}79.5$).

Other Non-current Financial Assets

A J 30, 2024, $\text{¥}64.3$ (D 31, 2023: $\text{¥}65.1$).

Construction in progress

A J 30, 2024, $\text{¥}234.0$ (D 31, 2023: $\text{¥}157.0$). D $\text{¥}9.9$ (D $\text{¥}9.9$)
 A $\text{¥}1.8$ (D $\text{¥}1.8$)

Right-of-use Assets

A J 30, 2024, $\text{¥}170.5$ (D 31, 2023: $\text{¥}139.1$),
 A $\text{¥}0.0$ (D $\text{¥}0.0$)

Accounts Payables

A J 30, 2024, $\text{¥}112.5$ (D 31, 2023: $\text{¥}110.1$).

Management Discussion and Analysis

Receipts in Advance and Contract Liabilities

As of June 30, 2024, Receipts in Advance and Contract Liabilities were RMB26.3 million (December 31, 2023: RMB26.6 million).

Other Payables

As of June 30, 2024, Other Payables were RMB63.5 million (December 31, 2023: RMB150.3 million), primarily consisting of payables to related parties, payables to suppliers, and payables to employees.

As of June 30, 2024, Other Payables were primarily composed of payables to related parties, payables to suppliers, and payables to employees. The breakdown is as follows:

For the six months ended June 30,
 2024 2023
 (RMB'000) (RMB'000)
 (Unaudited) ()

Payables to related parties	116,536	113,591
Payables to suppliers	-112,711	-119,122
Payables to employees	-41,660	9,790
Other payables	-37,934	4,273

Net Cash Generated from Operating Activities

During the six months ended June 30, 2024, Net Cash Generated from Operating Activities was RMB116.5 million, an increase of RMB45.0 million compared to RMB71.5 million for the same period in 2023. The increase was primarily due to an increase in net cash generated from operating activities, offset by an increase in net cash used in investing activities.

Net Cash Used in Investing Activities

During the six months ended June 30, 2024, Net Cash Used in Investing Activities was RMB112.7 million, an increase of RMB11.0 million compared to RMB101.7 million for the same period in 2023. The increase was primarily due to an increase in net cash used in investing activities, offset by an increase in net cash generated from operating activities.

Management Discussion and Analysis

Net Cash Generated from Financing Activities

D 41.7 million yuan, an increase of 41.7 million yuan compared to 2023.

Significant Investment, Acquisition and Disposal

G 100 million yuan, an increase of 100 million yuan compared to 2023.

A 100 million yuan, an increase of 100 million yuan compared to 2023.

Bank Borrowings

A 31, 2023: B364.7 million yuan, an increase of 364.7 million yuan compared to 2022.

Contingent Liability

A 30, 2024, G 100 million yuan, an increase of 100 million yuan compared to 2023.

Asset Pledge

D 41.7 million yuan, an increase of 41.7 million yuan compared to 2023. G 100 million yuan, an increase of 100 million yuan compared to 2023. H 100 million yuan, an increase of 100 million yuan compared to 2023.

Management Discussion and Analysis

Lease Liabilities

At 30 June 2024, the Group's lease liabilities were B22.5 million (B153.9 million at 30 June 2023). The Group has entered into several lease contracts for office premises and equipment. The Group uses the short-term lease exemption for leases with a maximum term of 12 months and does not recognize lease liabilities for these leases.

Financial Instruments

The Group's financial instruments include cash and bank balances, trade receivables, trade payables, and other receivables and payables. The Group's financial instruments are classified as financial assets and financial liabilities. The Group's financial instruments are measured at fair value.

Exposure to Fluctuation in Exchange Rates

The Group is exposed to exchange rate fluctuations primarily through its trade receivables and trade payables denominated in US dollars. The Group's functional currency is the Hong Kong dollar (HKD). The Group uses natural hedging to manage its exchange rate risk. The Group's trade receivables and trade payables are denominated in HKD and US dollars. The Group's trade receivables are denominated in US dollars, and the Group's trade payables are denominated in HKD. The Group's exchange rate risk is managed through natural hedging.

Gearing Ratio

At 30 June 2024, the Group's gearing ratio (total debt divided by total equity) was 52.6% (53.3% at 30 June 2023). The Group's total debt was B22.5 million at 30 June 2024, and its total equity was B42.7 million. The Group's total debt was B153.9 million at 30 June 2023, and its total equity was B286.5 million.

Employees and Remuneration Policy

At 30 June 2024, the Group had 4,742 employees (4,765 employees at 30 June 2023). The Group's remuneration policy is designed to attract, retain and motivate employees. The Group's remuneration policy is based on the employee's performance, experience and qualifications. The Group's remuneration policy is approved by the Board of Directors. The Group's remuneration policy is to provide a competitive and fair remuneration package to its employees.

The Group's remuneration policy is to provide a competitive and fair remuneration package to its employees. The Group's remuneration policy is based on the employee's performance, experience and qualifications. The Group's remuneration policy is approved by the Board of Directors. The Group's remuneration policy is to provide a competitive and fair remuneration package to its employees.



Management Discussion and Analysis

E 1 1 1 1 1

1. 2018 年 12 月 31 日，本公司 2018 年股权激励計劃（“Equity Incentive Scheme”）已獲准。根據該計劃，本公司將向合資格的高級管理人員和核心技術人員授予股票期權。該計劃旨在吸引和留住人才，並激勵他們為公司的長期發展做出貢獻。

2. 2019 年 1 月 1 日，該計劃開始實施。截至 2019 年 12 月 31 日，共有 10 名員工獲得了股票期權。這些期權將於 2020 年 1 月 1 日開始生效。根據該計劃，獲授期權的員工必須在 2020 年 1 月 1 日前開始工作，並在公司服務至少三年。

3. 根據該計劃，獲授期權的員工必須在 2020 年 1 月 1 日前開始工作，並在公司服務至少三年。如果員工在服務期間內離職，則其獲授的期權將被沒收。此外，該計劃還規定了其他條款，包括期權的行使價格、有效期等。

4. 本公司認為，該計劃將有助於提高員工的忠誠度和工作積極性，從而提高公司的競爭力。然而，該計劃也可能導致員工在短期內離職，從而影響公司的穩定性。因此，本公司將密切關注該計劃的實施情況，並根據需要進行調整。

5. 2020 年 1 月 1 日，該計劃開始實施。截至 2020 年 12 月 31 日，共有 15 名員工獲得了股票期權。這些期權將於 2021 年 1 月 1 日開始生效。根據該計劃，獲授期權的員工必須在 2021 年 1 月 1 日前開始工作，並在公司服務至少三年。

6. 根據該計劃，獲授期權的員工必須在 2021 年 1 月 1 日前開始工作，並在公司服務至少三年。如果員工在服務期間內離職，則其獲授的期權將被沒收。此外，該計劃還規定了其他條款，包括期權的行使價格、有效期等。

7. 本公司認為，該計劃將有助於提高員工的忠誠度和工作積極性，從而提高公司的競爭力。然而，該計劃也可能導致員工在短期內離職，從而影響公司的穩定性。因此，本公司將密切關注該計劃的實施情況，並根據需要進行調整。

8. 2021 年 1 月 1 日，該計劃開始實施。截至 2021 年 12 月 31 日，共有 20 名員工獲得了股票期權。這些期權將於 2022 年 1 月 1 日開始生效。根據該計劃，獲授期權的員工必須在 2022 年 1 月 1 日前開始工作，並在公司服務至少三年。

9. 根據該計劃，獲授期權的員工必須在 2022 年 1 月 1 日前開始工作，並在公司服務至少三年。如果員工在服務期間內離職，則其獲授的期權將被沒收。此外，該計劃還規定了其他條款，包括期權的行使價格、有效期等。

10. 本公司認為，該計劃將有助於提高員工的忠誠度和工作積極性，從而提高公司的競爭力。然而，該計劃也可能導致員工在短期內離職，從而影響公司的穩定性。因此，本公司將密切關注該計劃的實施情況，並根據需要進行調整。

Management Discussion and Analysis

• E



(1)

E

C

G

C

E

A

A

(2)

()

A

G

E

D

G

B

36

E

() E

B

Management Discussion and Analysis

- (5) $G \rightarrow \text{A} \bullet$ $E \rightarrow \text{A} \bullet$
- (a) $\text{A} \rightarrow \text{A} \bullet$ $\text{A} \rightarrow \text{A} \bullet$ $\text{A} \rightarrow \text{A} \bullet$ $\text{A} \rightarrow \text{A} \bullet$
- (b) $C \rightarrow \text{A} \bullet$ $zD \rightarrow \text{A} \bullet$ $G \rightarrow D \bullet$
- (m) $\text{A} \rightarrow \text{A} \bullet$ $zD \rightarrow \text{A} \bullet$ $\text{A} \rightarrow C \bullet$

Management Discussion and Analysis

Table 1: Changes in the Number of Restricted Stock Shares Held by the Company's Directors, Supervisors, and Senior Management Personnel as of June 30, 2024.

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of	Balance of	Granted during the Reporting Period	Vested	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024		(Unlocked) during the Reporting Period			Granted but not Vested as at June 30, 2024
Director Mr. A G	Jan 13, 2021	Jan 28, 2022	10.47		243,328					
Director Mr. IE	Jan 13, 2021	Jan 28, 2022	10.47		4,776					
Director Mr. G (Director Mr. A G's spouse)	Jan 13, 2021	Jan 28, 2022	10.47		23,653					Director Mr. J Director Mr. J

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/ Share)	Balance of	Balance of	Granted during the Reporting Period	Vested	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of
				Incentive Shares Granted but not Vested as at January 1, 2024	Incentive Shares Granted and Vested as at January 1, 2024		(Unlocked) during the Reporting Period			Incentive Shares Granted but not Vested as at June 30, 2024

١١ ١٢ ١٣ ()



Management Discussion and Analysis

本公司 2024 年 1-3 月实现营业收入 1,240,100 元，较上年同期增加 1.66%。其中，H 类业务收入 364,100 元，较上年同期增加 36%；A 类业务收入 335,000 元，较上年同期增加 52%；C 类业务收入 75,000 元，较上年同期增加 7%。此外，B 类业务收入 101,000 元，较上年同期增加 101%；D 类业务收入 1,240,100 元，较上年同期增加 1,240,100%。以上数据反映了公司在报告期内营业收入的稳步增长，主要得益于 H 类和 A 类业务的强劲表现。同时，B 类和 D 类业务也实现了显著增长，进一步推动了公司整体营收的提升。

截至 2024 年 3 月 31 日，公司总资产为 616,000 元，较年初增加 36%。其中，流动资产 364,100 元，较年初增加 36%；非流动资产 251,900 元，较年初增加 36%。负债总额为 335,000 元，较年初增加 52%。所有者权益为 281,000 元，较年初增加 36%。以上数据表明，公司在报告期内保持了良好的财务状况，资产和所有者权益均实现了稳步增长。同时，负债的增加也反映了公司在运营过程中对资金的需求。未来，公司将进一步优化资产结构，提高资金使用效率，确保公司持续健康发展。

2024 年 1-3 月，公司净利润为 18,204 元。

2023 年 1-3 月，公司净利润为 27,203 元。

Corporate Governance and Other Information

C, A E G E A CE
D CGC
C IA CE I H HE DE C DE
C C C C C D

Corporate Governance and Other Information

本公司根據《中華人民共和國企業所得稅法》（「企業所得稅法」）及《中華人民共和國企業所得稅法實施條例》（「實施條例」）的規定，本公司在中國大陸境內及境外所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。

本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。本公司在中國大陸境內及境外的所得，均應繳納企業所得稅。

Corporate Governance and Other Information

CHA GEI DI EC	, , E I	A D E I	A AGE E
2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	D1 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	C 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>
E E	AF E HE E	I G, E I D	
2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	G 2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>	2023 12 31 <input checked="" type="checkbox"/> 2023 12 31 <input checked="" type="checkbox"/>
CHA GEI DI EC	, , E I	' A D CHIEF E EC	I E'

Corporate Governance and Other Information

DI C E F I E E

Directors', Supervisors' and Chief Executive's Interests in Securities

As of June 30, 2024, the interests in securities of the Directors, Supervisors and Chief Executive are as follows:

(1) Mr. Guo Aimin: 19,340,300 H Shares, 74,600,300 C Shares, 55,260,000 D Shares.

(2) Mr. Guo Aimin and Mr. Guo Aimin: 3,694,500 C Shares, 19,350,250 H Shares.

(3) Mr. Guo Aimin: 4,540,000 D Shares.

Name of Directors	Class of Shares	Nature of Interest	Number of Shares	Total Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares ⁽¹⁾
Mr. Guo Aimin ⁽²⁾	D	Direct	19,350,250 () 3,694,500 ()	22,044,750 ()	39.99%	29.55%
Mr. Guo Aimin ⁽²⁾	D	Direct	3,694,500 () 19,350,250 ()	22,044,750 ()	39.99%	29.55%
	H	Direct	149,300 ()	149,300 ()	0.77%	0.20%
Mr. Guo Aimin	D	Direct	100,000 ()	100,000 ()	0.13%	0.13%
	H	Direct	159,100 ()	159,100 ()	0.82%	0.21%
Mr. Guo Aimin ⁽³⁾	D	Direct	4,540,000 ()	4,540,000 ()	3.22%	6.09%

(1) The total number of shares of the Company is 55,260,000 D Shares, 19,340,300 H Shares, and 74,600,300 C Shares as of June 30, 2024.

(2) Mr. Guo Aimin and Mr. Guo Aimin are the same person. Mr. Guo Aimin is the Chairman of the Board of Directors and the Chief Executive Officer of the Company. Mr. Guo Aimin is also the Chairman of the Board of Directors and the Chief Executive Officer of the Company.

(3) Mr. Guo Aimin is the Chairman of the Board of Directors and the Chief Executive Officer of the Company. Mr. Guo Aimin is also the Chairman of the Board of Directors and the Chief Executive Officer of the Company.

Corporate Governance and Other Information

As of December 31, 2024, the Company has 352 shareholders, including 100,000,000 shares of Class A ordinary shares, 7,466,666 shares of Class D shares, 4,540,000 shares of Class E shares, and 4,540,000 shares of Class F shares. The Company has 10 directors, 3 independent non-executive directors, and 3 supervisors. The Company has 10 subsidiaries, including 7 wholly-owned subsidiaries, 2 majority-owned subsidiaries, and 1 minority-owned subsidiary. The Company has 10 subsidiaries, including 7 wholly-owned subsidiaries, 2 majority-owned subsidiaries, and 1 minority-owned subsidiary.

Interests of Substantial Shareholders

As of December 31, 2024, the Company has 336 substantial shareholders. The Company has 10 directors, 3 independent non-executive directors, and 3 supervisors. The Company has 10 subsidiaries, including 7 wholly-owned subsidiaries, 2 majority-owned subsidiaries, and 1 minority-owned subsidiary. The Company has 10 subsidiaries, including 7 wholly-owned subsidiaries, 2 majority-owned subsidiaries, and 1 minority-owned subsidiary.

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
中央企業鄉村產業投資基金股份有限公司 (Central Enterprise Rural Industry Investment Fund Co., Ltd.)	D 股	直接持有	7,466,666 ()	13.51%	10.00%
上海金浙企業管理中心(有限合夥) ⁽²⁾ (Shanghai Jinzhe Enterprise Management Center (Limited Partnership))	D 股	直接持有	4,540,000 ()	5.22%	6.09%
FA 公司 ⁽²⁾	D 股	直接持有	4,540,000 ()	5.22%	6.09%
J 公司 ⁽²⁾	D 股	直接持有	4,540,000 ()	5.22%	6.09%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
上海金浦健服股權投資管理有限公司 ⁽²⁾ (上海金浦健服股權投資管理有限公司) ⁽²⁾	D	直接	4,540,000()	3.22%	6.09%
溫州金寧股權投資合夥企業(有限合夥) (溫州金寧股權投資合夥企業(有限合夥))	D	直接	4,540,000()	3.22%	6.09%
上海金浦健服股權投資管理有限公司 ⁽²⁾ (上海金浦健服股權投資管理有限公司) ⁽²⁾	D	直接	3,934,350()	7.21%	5.34%
上海檀英投資合夥企業(有限合夥) (上海檀英投資合夥企業(有限合夥))	D	直接	4,519,003()	3.13%	6.06%
上海樂進投資合夥企業(有限合夥) ⁽³⁾ (上海樂進投資合夥企業(有限合夥)) ⁽³⁾	D	直接	4,519,003()	3.13%	6.06%
上海正心谷投資管理有限公司 (上海正心谷投資管理有限公司)	D	直接	6,506,309()	11.77%	3.72%
上海盛歌投資管理有限公司 ⁽⁴⁾ (上海盛歌投資管理有限公司) ⁽⁴⁾	D	直接	6,506,309()	11.77%	3.72%
萬得信息技術股份有限公司 (萬得信息技術股份有限公司)	D	直接	3,333,000()	6.03%	4.47%
上海荷花緣企業管理中心(有限合夥) (上海荷花緣企業管理中心(有限合夥))	D	直接	3,333,000()	6.03%	4.47%

Corporate Governance and Other Information

▼ :

(): 74,600,300

(1) 55,260,000 D 19,340,300 H ()
74,600,300) C J 30, 2024.

(2) FA 50% () () (上海金浙企業管理中心(有限
合夥企業)

ASSETS	I	Balance as at the end of the period	B - γ
Current assets:			
C	(γ)	373,302,433.47	418,861,721.39
F	(η)	7,599,178.13	7,350,298.53
D	(μ)	763,849.74	
A	(γ)	448,102,421.02	420,441,069.56
A	()	2,366,951.74	9,830,552.98
	(γ)	69,943,027.66	69,705,728.98
F	(η)	51,889,640.76	60,600,180.25
A	(μ)	3,053,787.78	88,020.39
Total current assets		957,021,290.30	987,647,572.08

Consolidated Balance Sheets

2024年12月31日

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

ASSETS	Balance as at the end of the period	Balance as at the end of the period
Non-current assets:		
Land use rights	(元)	14,000,000.00
Intangible assets	(元)	141,550,815.01
Long-term equity investments	(元)	64,751,652.55
Investments in subsidiaries	(元)	782,127,103.00
Investments in associates	(元)	234,034,296.61
Investments in joint ventures	(元)	170,465,125.54
Other non-current assets	(元)	307,875,476.38
Prepaid expenses	(元)	119,909,089.24
Receivables	(元)	156,750,581.45
Other receivables	(元)	44,940,518.91
Other non-current assets	(元)	14,925,823.45
Total non-current assets	2,051,330,482.14	2,060,039,034.76
Total assets	3,008,351,772.44	3,047,636,606.84

GUAN Weili
JIN Hui
WANG Minhui

LIABILITIES AND SHAREHOLDERS' EQUITY	I	Balance as at the end of the period	B - γ
Current liabilities:			
	(γ)	111,000,000.00	127,001,700.00
	(γ)	12,400,000.00	12,400,000.00
			1,545,021.09
	(מ)	112,544,938.03	110,060,007.67
	(γ)	26,157,511.69	26,563,603.06
	()	92,924.53	
	(γ)	67,014,464.52	84,324,006.40
	(γ)	30,855,445.81	38,553,746.47
	(מ)	68,487,137.05	150,270,575.15
	(γ)	108,286,381.25	250,411,756.99
	()	569,425.21	
Total current liabilities		537,408,228.09	801,130,416.83
Non-current liabilities:			
	(γ)	768,224,669.65	557,719,214.69
	(מ)	158,912,952.10	163,239,532.76
	(מ)	64,227,913.88	61,351,340.53
	(γ)	8,582,203.00	8,734,099.00
	(מ)	44,533,949.56	47,306,056.21
Total non-current liabilities		1,044,481,688.19	838,350,243.19



Consolidated Balance Sheets

June 30, 2024

(Amount in thousands of RMB)

	I	Balance as at the end of the period	B 千元
LIABILITIES AND SHAREHOLDERS' EQUITY			

Parent Company Balance Sheets

June 30, 2024

(As of June 30, 2024)

		Balance as at the end of the period	Balance at the beginning of the period
ASSETS			
Current assets:			
Cash and cash equivalents		167,239,404.12	136,337,559.21
Accounts receivable			
Prepaid expenses and other receivables			
Inventory			
Property, plant, and equipment	(1)	55,989,746.68	48,066,557.69
Goodwill			
Intangible assets			
Other non-current assets		6,900.00	228,131.12
Investments	(1)	622,922,583.60	600,448,325.58
Other current assets		9,687,901.11	11,131,002.59
Deferred tax assets			
Other assets			
Other non-current assets		355,000.00	330,000.00
Total current assets		856,201,535.51	847,091,576.19

Parent Company Balance Sheets

June 30, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

		Balance as at the end of the period	Balance as at the end of the period
ASSETS	I		II
Non-current assets:			
Long-term equity investments			
Investments in subsidiaries	(m)	793,380,629.16	785,953,439.17
Investments in associates			
Investments in joint ventures		64,751,652.55	65,099,055.34
Other long-term equity investments			
Available-for-sale financial assets		283,949,624.57	283,701,322.35
Fixed assets		394,874.50	113,600.00
Property, plant and equipment			
Intangible assets			
Goodwill			
Other intangible assets			
Right-of-use assets		23,105,075.42	23,650,002.23
Deferred tax assets			
Other non-current assets			
Long-term prepayments			
Long-term receivables			
Long-term contract assets			
Long-term contract liabilities			
Long-term receivables			
Long-term contract assets			
Long-term contract liabilities			
Other non-current assets		16,120,799.75	15,459,271.72
Other non-current assets		16,099,597.14	14,605,690.36
Other non-current assets		14,472,217.77	6,320,355.26
Total non-current assets		1,212,274,470.86	1,202,965,769.43
Total assets		2,068,476,006.37	2,050,057,345.62

(Signature) (Name) (Title) (Date)

A (Signature) (Name) (Title) (Date)
GUAN Weili

C (Signature) (Name) (Title) (Date)
JIN Hui

H (Signature) (Name) (Title) (Date)
WANG Minhui

Parent Company Balance Sheets

June 30, 2024

(As of June 30, 2024)

	Balance as at the end of the period	Balance as at the end of the period
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	111,000,000.00	125,000,000.00
Accounts receivable		
Other receivables		
Prepaid expenses		
Accrued liabilities		
Income taxes payable		
Other current liabilities		
Total current liabilities	273,238,064.38	397,653,449.25
Non-current liabilities:		
Long-term debt	506,300,000.00	362,042,127.25
Deferred tax liabilities		
Other non-current liabilities		
Total non-current liabilities	531,592,777.36	396,631,460.33
Total liabilities	804,830,841.74	794,284,910.13



Parent Company Balance Sheets

June 30, 2024

(Amount in RMB)

	Balance as at the end of the period	Balance as at the beginning of the period
LIABILITIES AND SHAREHOLDERS' EQUITY		
Shareholders' equity:		
Capital	74,600,300.00	74,600,300.00
Reserves:		
Surplus reserves	862,663,919.13	871,230,628.64
Other reserves	3,146,832.71	12,537,011.74
Minority interest	38,399,577.13	38,399,577.13
Total shareholders' equity	1,263,645,164.63	1,255,767,435.49
Total liabilities and shareholders' equity	2,068,476,006.37	2,050,057,345.62

GUAN Weili JIN Hui WANG Minhui
 Director Director Director
 Chairman Chairman Chairman
 GUAN Weili JIN Hui WANG Minhui
 Director Director Director
 Director Director Director

Consolidated Income Statement

For the six months ended June 30, 2024

(All amounts in RMB Yuan unless otherwise stated)

Item	Unit	Amount for the current period	Amount for the corresponding period of the previous year
III. Operating profit (losses represented with "-" sign)		63,825,306.45	56,497,252.53
A. Operating profit (losses represented with "-" sign)	(元)	503,489.95	5,924,960.95
B. Operating profit (losses represented with "-" sign)	(元)	2,816,219.76	2,215,131.37
IV. Total profit (total losses represented with "-" signs)		61,512,576.64	60,207,112.14
C. Total profit (total losses represented with "-" signs)	(元)	16,516,143.35	11,477,550.07
V. Net profit (net losses represented with "-" signs)		44,996,433.29	48,729,232.07
(一) C. Net profit (net losses represented with "-" signs)			
1. Net profit (net losses represented with "-" signs)	(元)	44,996,433.29	48,729,232.07
2. Net profit (net losses represented with "-" signs)	(元)		
(二) C. Net profit (net losses represented with "-" signs)			
1. Net profit (net losses represented with "-" signs)	(元)	50,723,744.20	43,750,057.46
2. Net profit (net losses represented with "-" signs)	(元)	-5,727,310.91	4,979,174.61
VI. Other comprehensive income, net of tax			
(一) Other comprehensive income, net of tax			
(一) Other comprehensive income, net of tax			
1. C. Other comprehensive income, net of tax	(元)		
2. Other comprehensive income, net of tax	(元)		
3. C. Other comprehensive income, net of tax	(元)		
4. C. Other comprehensive income, net of tax	(元)		

Parent Company Income Statement

F 2024 年 6 月 30 日
 (A 股上市) (B 股上市)

Item	Amount for the current period	A 股	B 股
V. Other comprehensive income, net of tax			
(a) 其他综合收益			
1. 可供出售金融资产公允价值变动			
2. 其他权益工具投资公允价值变动			
3. 现金流量套期工具公允价值变动			
4. 外币财务报表折算差额			
(b) 其他综合收益			
1. 可供出售金融资产公允价值变动			
2. 其他权益工具投资公允价值变动			
3. 现金流量套期工具公允价值变动			
4. 外币财务报表折算差额			
5. 其他			
6. 其他			
7. 其他			
VI. Total comprehensive income	29,384,349.62	-3,676,344.29	
VII. Earnings per share:			
(a) B 股 (每股)			
(b) D 股 (每股)			

董事: GUAN Weili, JIN Hui, WANG Minhui
 监事: H
 财务总监:

Item	Amount for the current period	A	
I. Cash flows from operating activities			
C 1. Receipts from sales of goods and services	774,736,897.94	780,036,767.35	
C 2. Receipts from operating activities other than sales of goods and services			
C 3. Receipts from interest			
C 4. Receipts from dividends			
C 5. Receipts from disposal of long-term assets			
C 6. Receipts from disposal of long-term investments			
C 7. Receipts from disposal of subsidiaries and equity investments			
C 8. Receipts from financing activities other than borrowings			
C 9. Receipts from government grants			
C 10. Receipts from disposal of other financial assets			
C 11. Receipts from other operating activities			
C Sub-total of cash inflows of operating activities	814,801,465.74	949,990,763.62	
C 1. Payments for purchase of goods and services			
C 2. Payments for operating activities other than purchases of goods and services			
C 3. Payments for interest			
C 4. Payments for dividends			
C 5. Payments for acquisition of long-term assets			
C 6. Payments for acquisition of long-term investments			
C 7. Payments for acquisition of subsidiaries and equity investments			
C 8. Payments for financing activities other than borrowings			
C 9. Payments for government grants			
C 10. Payments for other financial assets			
C 11. Payments for other operating activities			
C Sub-total of cash outflows of operating activities	698,265,482.13	836,399,424.92	
Net cash flows from operating activities	116,535,983.61	113,591,338.70	

Consolidated Cash Flow Statement

For the six months ended June 30, 2024

(All amounts in RMB Yuan unless otherwise stated)

Item	Amount for the current period	A	1	10
II. Cash flows from investing activities				
C				8,249,457.77
▼ C				
▼		644,865.42		26,353.01
▼		432,733.42		
C		1,077,598.84		8,275,840.78
C		111,001,022.93		107,843,620.41
▼ C		2,000,000.00		3,866,900.00
▼				15,187,013.06
C		787,500.00		500,059.94
-		113,788,522.93		127,397,593.41

Item	Amount for the current period	A 元	元
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-99,244.67		13,070.04
V. Net increase in cash and cash equivalents	-37,934,050.43		4,272,913.65
A ● : C 元 ● 元 元 元 元	404,723,339.37	253,595,990.97	
VI. Cash and cash equivalents at the end of the period	366,789,288.94	262,363,904.62	

元 元 元 元 元 元

元 元 元 元
GUAN Weili

元 元 元 元 元 元
JIN Hui

H ● 元 元 元 元
WANG Minhui

Parent Company Cash Flow Statement

Fiscal Year Ending June 30, 2024

(Amounts in thousands of US dollars)

Item	Amount for the current period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from customers	178,625,474.28	186,510,657.37
Cash received from other sources	334,259,258.00	491,763,053.70
Sub-total of cash in flows of operating activities	512,884,732.28	678,273,711.07
Cash paid for operating expenses	66,197,024.94	80,195,550.90
Cash paid for interest	84,545,764.25	80,391,274.33
Cash paid for income taxes	2,949,959.92	433,577.67
Cash paid for other operating activities	338,808,072.60	463,041,604.81
Sub-total of cash out flows of operating activities	492,500,821.71	624,567,307.71
Net cash flows from operating activities	20,383,910.57	53,706,403.36
II. Cash flows from investing activities:		
Cash received from the sale of property and equipment		16,657,744.50
Cash received from the sale of investments	13,273,818.98	
Cash received from other investing activities	10,427.00	
Cash paid for the acquisition of property and equipment		
Cash paid for the acquisition of investments		
Cash paid for other investing activities		
Sub-total of cash in flows of investing activities	13,284,245.98	16,657,744.50
Cash paid for the acquisition of property and equipment	1,277,334.63	1,691,749.51
Cash paid for the acquisition of investments	7,200,000.00	29,166,900.00
Cash paid for other investing activities		
Sub-total of cash out flows of investing activities	8,477,334.63	30,858,649.51
Net cash flows from investing activities	4,806,911.35	-14,200,905.01



Parent Company Cash Flow Statement

For the period from January 1, 2024 to June 30, 2024

(Amount in thousands of RMB)

Item	Amount for the current period	Amount for the corresponding period of the previous year
III. Cash flows from financing activities:		
Cash received from issuing bank deposits	293,000,000.00	199,050,000.00
Cash received from issuing bank loans		
Cash received from issuing other financial instruments		
Sub-total of cash inflows of financing activities	293,000,000.00	199,050,000.00
Cash paid for repaying bank deposits	276,792,127.25	101,150,000.00
Cash paid for repaying bank loans	35,406,263.84	12,364,450.26
Cash paid for repaying other financial instruments	25,472,250.00	79,243,750.00
Sub-total of cash outflows of financing activities	337,670,641.09	192,758,200.26
Net cash flows from financing activities	-44,670,641.09	6,291,799.74
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-119,720.72	13,070.04
V. Net increase in cash and cash equivalents	-19,599,539.89	45,810,373.13
Balance at the beginning of the period	185,475,808.48	90,387,144.89
VI. Cash and cash equivalents at the end of the period	165,876,268.59	136,197,518.02

Prepared by: [Signature] Date: [Signature]

Accountant:
GUAN Weili

Accountant:
JIN Hui

Accountant:
WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

For the period from January 1, 2024 to June 30, 2024

(Amounts in millions of US dollars)

Items	Amount for the current period													
	Share capital	Preferred shares	Perpetual bonds	Other	Capital reserve	Treasury stock	Less: comprehensive income	Special reserves	Surplus reserves	Provision for general risk	Retained earnings	Subtotal	Minority interests	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				862,695,601.69	12,587,011.74			38,399,577.13		317,956,229.16	1,265,064,696.24	143,141,250.58	1,408,205,946.82
II. Balance as at the beginning of the current year	74,600,300.00				862,695,601.69	12,587,011.74			38,399,577.13		317,956,229.16	1,265,064,696.24	143,141,250.58	1,408,205,946.82
III. Increases/decreases in the current period (· for increases)					-11,942,210.95	-9,440,179.03					28,343,654.20	25,847,722.28	-7,565,802.94	18,255,909.34
(a) 1. C											50,723,744.20	50,723,744.20	-5,727,310.91	44,996,433.29
2. C					-8,566,709.51	-9,440,179.03						873,469.52	1,033,024.97	1,906,494.49
3. A					-9,334,383.19	-9,440,179.03						106,746.34	1,033,024.97	1,138,820.81
4. D					767,673.68								767,673.68	767,673.68
(b) 1. D											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
2. D														
3. D														
4. D														
(c) 1. C											-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00

		E		A		C		B		D	
		元		元		元		元		元	
		12月31日		12月31日		12月31日		12月31日		12月31日	
I.	Balance as at the end of the previous year	74,600,300.00	38,990,577.13	233,505,534.43	1,201,534,944.86	124,377,673.97	1,325,902,618.83				
(a)	C										
(b)	C										
(c)	B										
II.	Balance as at the beginning of the current year	74,600,300.00	38,990,577.13	233,505,534.43	1,201,534,944.86	124,377,673.97	1,325,902,618.83				
III.	Increase/decrease in the current period ("+" for increases)										
(1)	1. C										
(2)	2. C										
(3)	3. A										
(4)	4.										
(5)	(a) 1. D										
(6)	(b) 1. D										
(7)	2. D										
(8)	3. D										
(9)	4.										
(10)	(a) 1. C										
(11)	2. C										
(12)	3.										
(13)	4. C										
(14)	5. C										
(15)	6.										
(16)	(1)										
(17)	2.										
IV.	Balance as at the end of the period	74,600,300.00	38,990,577.13	311,955,223.16	1,285,054,656.24	143,141,255.58	1,408,205,946.92				

关卫利
 GUAN Weili
 王敏辉
 WANG Minhui

Parent Company Statement of Changes in Shareholders' Equity

F 1 1 1 1 J 30, 2024

(A 1 1 B 1 1)

Items	Amount for the current period										
	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Treasury stock	Less: comprehensive income	Special reserves	Surplus reserves	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
A. C 1 1 1 1 1 1											
C 1 1 1 1 1 1											
II. Balance as at the beginning of the current year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
III. Increases/decreases in the current period ("+" for increases)					-8,566,709.51	-9,440,179.03			7,004,259.62	29,384,349.62	7,877,729.14
(1) 1 1 1 1 1 1											
(2) 1 1 1 1 1 1											
1. C 1 1 1 1 1 1					-8,566,709.51	-9,440,179.03					873,469.52
2. C 1 1 1 1 1 1					-9,334,383.19	-9,440,179.03					105,795.84
3. A 1 1 1 1 1 1											
4. 1 1 1 1 1 1											
(3) 1 1 1 1 1 1					767,673.68						767,673.68
1. 1 1 1 1 1 1											
2. 1 1 1 1 1 1											
3. 1 1 1 1 1 1											
(4) 1 1 1 1 1 1											
1. C 1 1 1 1 1 1											
2. C 1 1 1 1 1 1											
3. C 1 1 1 1 1 1											
4. C 1 1 1 1 1 1											
5. C 1 1 1 1 1 1											
6. 1 1 1 1 1 1											
(5) 1 1 1 1 1 1											
1. 1 1 1 1 1 1											
2. 1 1 1 1 1 1											
IV. Balance as at the end of the period	74,600,300.00				862,663,919.13	3,146,832.71			38,399,577.13	291,128,201.08	1,263,645,164.63

1. JIN Hui
 2. WANG Minhui
 3. GUAN Weili

Parent Company Statement of Changes in Shareholders' Equity

For the period from January 1, 2024 to June 30, 2024

(Amount in RMB)

	A	B	C	D	E	F
	Balance at the beginning of the year	Issue of shares	Share repurchase	Change in capital reserve	Change in other reserves	Change in retained earnings
I. Balance as at the end of the previous year	74,600,300.00					33,399,577.13
II. Balance as at the beginning of the current year	74,600,300.00					33,399,577.13
III. Increases/decreases in the current period ("+" for increases)						
(1) Issuance of shares						
(2) Share repurchase						
(3) Change in capital reserve						
(4) Change in other reserves				12,557,011.74		42,220,250.23
(5) Change in retained earnings						49,713,322.19
(6) Total				12,557,011.74		-12,557,011.74
IV. Balance as at the end of the period	74,600,300.00			12,557,011.74		241,903,691.13

Guan Weili
 JIN Hui
 Wang Minhui
 Guan Weili
 JIN Hui
 Wang Minhui

Notes to the Financial Statements

F J 30, 2024
 (A B)

I. G

H C . . . (zC)
 C H (溫州市康寧精神康復醫院) F 1996. C ' . . . H
 D , C.

15, 2014, C (溫州康寧醫院股份有限公司).

C E H 20, 2015.
 C

A J 30, 2024, C 19 90 ,600,300 0.5 () C

C , C.



Notes to the Financial Statements

F 2024 12 31

(A B)

II. B

(I) Basis of preparation

A B
 E B
 A B E A B
 E ()
 zA B E
 C D C 15
 G E C
 G E H C

A B E 32 E

G

Notes to the Financial Statements

F
(A

II. B (C

(II) Going concern

(III) Statement of compliance with the Accounting Standards for Business Enterprises

A B E J 30, 2024

III.

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate
(A)	A	

Notes to the Financial Statements

31 December 2024

(A) (B)

1. (A) (B) (C) (D) 31, 2023 (), 30, 2024 (), 30, 2024 (), 30, 2023 ().

(I) Cash at bank and on hand

Items	Balance as at the end of the period	B, ₪
C	315,188.51	371,623.69
C	367,196,561.26	416,930,293.93
	5,790,683.70	1,509,793.72
	<u>373,302,433.47</u>	<u>418,561,721.39</u>

(II) Financial assets held for trading

Items	Balance as at the end of the period	B, ₪
F	7,599,178.13	7,350,293.53
	7,599,178.13	7,350,293.53
	<u>7,599,178.13</u>	<u>7,350,293.53</u>

(III) Notes receivable

Items	Balance as at the end of the period	B, ₪
B	763,849.74	
	<u>763,849.74</u>	



Notes to the Financial Statements

For the period ended June 30, 2024

(Amounts in RMB)

1. Accounts receivable (continued)

(IV) Accounts receivable

1. Accounts receivable	Balance as at the end of the period	Balance as at the end of the period
Aging		B
1 year or less	443,637,522.96	425,833,221.01
1-2 years	42,631,127.19	6,696,709.84
2-3 years	4,507,504.01	4,480,032.80
3 years or more	10,140,966.30	7,780,009.57
-	500,917,120.46	444,789,973.22
Total	52,814,699.44	24,348,903.66
	448,102,421.02	420,441,069.56

2. Accounts receivable

Notes to the Financial Statements

F 1 1 1 • • J 30, 2024

(A 1 1 B 1 1 •)

I . 1 1 • • 1 1 (C 1 1 •)

(IV) Accounts receivable (Continued)

2. 1 1 1 • 1 1 • 1 1 1 1 1 1 • • (C 1 1 •)
 1 1 1 1 1 1 • • 1 1 1 1 1 :

	Balance as at the end of the period	B 1 1 1
	Provision for bad debts	1
Item	Book balance	1

Provision for bad debts 1433.7011 497.7061 cm0e

Notes to the Financial Statements

Financial statements for the period ending June 30, 2024

(Amounts in thousands of RMB)

1. Accounts receivable (Continued)

(IV) Accounts receivable (Continued)

Category	Balance as at the end of the period	Changes in the current period			Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	
Accounts receivable	24,348,903.66	17,050,089.50	-11,415,706.28		24,270,288.56
Allowance for doubtful accounts	11,494,321.35	17,050,089.50			28,544,410.88
	24,348,903.66	17,050,089.50	-11,415,706.28		52,814,699.44

(V) Advances to suppliers

Aging	Balance as at the end of the period		B	
	Amount	Proportion (%)	A	(%)
1	2,326,232.07	98.28	9,048,941.18	92.05
1-2			742,811.80	7.56
2-3	7,919.67	0.33	6,000.00	0.06
3	32,800.00	1.39	32,800.00	0.33

Notes to the Financial Statements

For the period ended June 30, 2024

(As at the end of the period)

1. (C) Other receivables

(VI) Other receivables

Items	Balance as at the end of the period	B
1	787,500.00	
	69,155,527.66	69,705,728.98
	69,943,027.66	69,705,728.98

1. 1

Items	Balance as at the end of the period	B
1	787,500.00	
	787,500.00	

2. (1) 1

Aging	Balance as at the end of the period	B
1	50,656,821.58	53,412,990.26
1 2	15,533,337.46	29,894,811.69
2 3	33,706,673.72	8,912,677.15
3 4	1,438,191.47	5,404,423.07
4 5	1,977,221.69	742,744.88
5	4,436,981.60	3,885,239.68
-	107,749,227.52	102,252,886.68
∴	38,593,699.86	32,547,157.70
	69,155,527.66	69,705,728.98



Notes to the Financial Statements

For the period from January 1, 2024 to December 31, 2024

(A: RMB million; B: US\$ thousand)

1. Other receivables (Continued) (CNY million)

(VI) Other receivables (Continued)

2. Other receivables (CNY million)

(2) Details of other receivables

Category	Balance as at the end of the period				Book value	B: US\$ thousand			
	Book balance		Provision for bad debts			B: US\$ thousand		B: US\$ thousand	
	Amount	Proportion (%)	Amount	Proportion (%)		A: US\$ thousand	Proportion (%)	A: US\$ thousand	Proportion (%)
Accounts receivable	36,761,735.90	34.12	36,761,735.90	100.00	37,404,736.41	36.5%	30,697,494.2%	32.07	6,707,242.13
Other receivables:									
Hospitals	23,066,977.13	21.41	23,066,977.13	100.00	23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13
Hospitals	10,204,311.69	9.47	10,204,311.69	100.00	10,204,311.69	9.9%	10,204,311.69	100.00	
C: (Long-term)	3,490,447.08	3.24	3,490,447.08	100.00	3,490,447.08	3.41	3,490,447.08	100.00	
Other receivables	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64.4%	1,849,663.42	2.45	62,934,446.45
Other receivables:									
Other receivables	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64.4%	1,849,663.42	2.45	62,934,446.45
	107,749,227.52	100.00	38,593,699.86		69,155,527.66	102,252,446.6%	100.00	32,547,157.70	69,705,724.9%

Notes to the Financial Statements

Fiscal year ended June 30, 2024
 (As of June 30, 2024)

1. Other receivables (Continued)

(VI) Other receivables (Continued)

2. Other receivables (Continued)

(2) Other receivables (Continued)

Name	Balance as at the end of the period			B Y	C Y
	Book balance	Provision for bad debts	Proportion of provision (%)		
H C	23,066,977.13	23,066,977.13	100.00	23,709,977.64	17,002,735.51
H C	10,204,311.69	10,204,311.69	100.00	10,204,311.69	10,204,311.69
C (長勝)	3,490,447.08	3,490,447.08	100.00	3,490,447.08	3,490,447.08
	36,761,735.90	36,761,735.90		37,404,736.41	30,697,494.28

Other receivables (Continued)

Other receivables (Continued)

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
	70,987,491.62	1,831,963.96	2.58
	70,987,491.62	1,831,963.96	

Notes to the Financial Statements

Financial statements for the period ending June 30, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

1. (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(VI) Other receivables (Continued)

2. (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

(3) (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

Provision for bad debts	Stage I	Stage II	Stage III	Total
	12-month ECL	Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)	1,349,663.42		30,697,494.28	32,547,157.70
B (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)			6,064,241.62	6,064,241.62
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)	17,423.93			17,423.93
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)	270.43			270.43
B (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)	1,831,963.96		36,761,735.90	38,593,699.86

Notes to the Financial Statements

Fiscal year ended June 30, 2024

(A) (B)

(C)

(VI) Other receivables *(Continued)*

2. (C)

(3) D (C)

C (C)

Book balance	Stage I	Stage II	Stage III	Total
	12-month ECL	Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
B	64,848,150.27		37,404,736.41	102,252,886.68
B				
		3(40 (C) 9 1.0733 D1)		

Notes to the Financial Statements

F 2024 12 31

(A B)

1. (C)

(VI) Other receivables (Continued)

2. (C)

(4)

Category	B	Changes in the current period			Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	
30,697,494.28	6,064,241.62			36,761,735.90	
1,349,663.42			17,428.98	270.48	1,831,963.96
32,547,157.70	6,046,241.62	17,428.98	270.48	38,593,699.86	

(5)

	Book balance as at the end of the period	B
D	22,840,821.05	22,266,761.49
E	25,289,000.00	19,150,000.00
	1,583,692.95	4,313,362.51
A	23,134.70	51,045.33
A	51,845,560.25	52,337,693.31
A	2,000,000.00	
	4,167,018.57	3,073,519.04
	107,749,227.52	102,252,336.68

Notes to the Financial Statements

For the period ended June 30, 2024

(As at the end of the period)

(CNY)

(VII) Inventories

Category	Balance as at the end of the period		B RMB	
	Book balance	Provision for decline in the value of inventories/impairment provision for contract performance costs	Book value	B RMB
	1,230,185.02		1,230,185.02	1,616,775.62
G	541,753.33		541,753.33	4,571,610.52
C	50,117,702.41		50,117,702.41	54,411,790.51
	51,889,640.76		51,889,640.76	60,600,150.25

(VIII) Other current assets

Items	Balance as at the end of the period	B RMB
Prepaid expenses	2,006,813.22	205,753.33
Other receivables		4,365.35
Other current assets	1,046,974.56	647,595.71
	3,053,787.78	553,020.39

(IX) Long-term receivables

Item	Balance as at the end of the period		B RMB	
	Book balance	Provision for bad debts	Book value	B RMB
Long-term receivables	14,000,000.00		14,000,000.00	14,000,000.00
	14,000,000.00		14,000,000.00	14,000,000.00

Notes to the Financial Statements

For the period ended June 30, 2024

(As of June 30, 2024)

1. Other non-current financial assets (CNY)

(XI) Other non-current financial assets

	Balance as at the end of the period	B RMB
1		
Financial assets	64,751,652.55	65,099,055.34
Financial assets at the end of the period	64,751,652.55	65,099,055.34
	64,751,652.55	65,099,055.34

(XII) Fixed assets

1. Fixed assets

Items	Balance as at the end of the period	B RMB
Fixed assets	782,127,103.00	794,356,342.94
Depreciation		
	782,127,103.00	794,356,342.94

Notes to the Financial Statements

F
(A)

I .

(XIII) Construction in progress

1. C

Items	Balance as at the end of the period			B	I	C
	Book balance	Impairment provision	Carrying amount	B	I	C
C	234,034,296.61		234,034,296.61	136,930,240.67		136,930,240.67
C						
	234,034,296.61		234,034,296.61	136,930,240.67		136,930,240.67

2. D

Items	Balance as at the end of the period			B	I	C
	Book balance	Impairment provision	Carrying amount	B	I	C
H	137,317,869.97		137,317,869.97	101,029,929.74		101,029,929.74
H	89,526,711.76		89,526,711.76	35,174,600.41		35,174,600.41
H	3,766,450.99		3,766,450.99			
H	3,423,263.89		3,423,263.89	775,710.52		775,710.52

Notes to the Financial Statements

F 2024 12 31

(A B C)

I. (C)

(XIV) Right-of-use assets

Items	Buildings and structure	Total
1. A		
(1) B	301,405,111.73	301,405,111.73
(2) C	70,403.22	70,403.22
	70,403.22	70,403.22
(3) D	1,131,535.34	1,131,535.34
	1,131,535.34	1,131,535.34
(4) B	300,343,934.11	300,343,934.11
2. A		
(1) B	112,350,605.05	112,350,605.05
(2) C	13,029,069.41	13,029,069.41
	13,029,069.41	13,029,069.41
(3) D	500,365.39	500,365.39
	500,365.39	500,365.39
(4) B	129,878,808.57	129,878,808.57
3. I		
(1) B		
(2) C		
(3) D		
(4) B		
4. C		
(1) C	170,465,125.54	170,465,125.54
(2) C	139,054,506.63	139,054,506.63

Notes to the Financial Statements

Fiscal year ended June 30, 2024

(As of June 30, 2024)

1. Intangible assets (CNY million)

(XV) Intangible assets

	Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management services	Total
1. As of June 30, 2024						

Notes to the Financial Statements

F 12 31, 2024

(A 12 31, 2024)

1. (C 12 31, 2024)

(XVI) Goodwill

1. C 12 31, 2024

Name of the investees or events generating goodwill	B 12 31, 2024	Increase in the current period		Decrease in the current period		Balance as at the end of the period
		Arising from business combination	Increase of provision for goodwill impairment	Disposal	Disposal of goodwill impairment	
1. A 12 31, 2024						
H 12 31, 2024	9,271,800.00					9,271,800.00
H 12 31, 2024	690,331.47					690,331.47
G 12 31, 2024	1,549,022.38					1,549,022.38
H 12 31, 2024	7,784,850.00					7,784,850.00
B 12 31, 2024	22,987,331.04					22,987,331.04
H 12 31, 2024	151,048.40					151,048.40
H 12 31, 2024	5,068,959.78					5,068,959.78
C 12 31, 2024	6,843,288.91					6,843,288.91
H 12 31, 2024	19,416,285.97					19,416,285.97
H 12 31, 2024	51,770,194.67					51,770,194.67
H 12 31, 2024	1,272,643.00					1,272,643.00
H 12 31, 2024	5,060,323.85					5,060,323.85
C 12 31, 2024	283,528.10					283,528.10
D 12 31, 2024	2,502,854.13					2,502,854.13
C 12 31, 2024	9,564,442.65					9,564,442.65
H 12 31, 2024	228,538.31					228,538.31
	144,445,442.66					144,445,442.66

Notes to the Financial Statements

F
(A)

(XVI) Goodwill (Continued)

2. $\text{B}^{\prime}0,000$

Name of goodwill asset groups or portfolio of asset groups	Composition and basis of asset groups or portfolio of asset groups	Carrying amount as at the end of the period	Consistent with the prior years or not
H	A	1,342.46	y
H	A	1,645.65	y
G	A	1,074.50	y
	A	771.11	y
B	A	4,178.64	y
	A	14.48	y
H	A	552.41	y
C	A	1,278.50	y
	A	3,726.83	y
	A	12,548.35	y
H	A	181.32	y
	A	7,011.47	y
	A	2,485.39	y
D	A	2,179.53	y
C	A	2,792.84	y
	A	4.09	y
		41,787.57	

Notes to the Financial Statements

For the period ended June 30, 2024

(All amounts are in RMB unless otherwise specified)

1. Long-term prepaid expenses (continued)

(XVII) Long-term prepaid expenses

Items	Balance at the beginning of the period	Increase in the current period	Amortisation in the current period	Balance as at the end of the period
Prepaid expenses	175,706,029.27	1,863,337.07	21,012,423.47	156,556,942.87
Prepaid insurance	178,292.93	38,000.00	41,641.68	174,651.25
Prepaid maintenance	26,303.94		7,316.61	18,987.33
	175,910,626.14	1,901,337.07	21,061,381.76	156,750,581.45

(XVIII) Deferred tax assets and deferred tax liabilities

1. Deferred tax assets

Items	Balance as at the end of the period		Change in the current period	
	Deductible temporary differences	Deferred tax assets	Change in the current period	Balance at the beginning of the period
Income tax	37,735,416.76	7,995,190.93	25,318,013.56	5,221,670.24
Other	36,307,991.72	9,076,997.93	3,073,067.80	3,073,067.80
Deductible temporary differences	94,761,661.96	18,358,697.14	126,627,704.89	26,623,506.01
Deferred tax assets	178,203,515.38	44,007,128.21	181,046,756.88	45,261,689.23
Non-deductible temporary differences	55,456,176.01	8,308,050.85	54,688,502.33	8,203,275.35
	402,464,761.83	87,746,065.06	390,754,045.46	88,383,203.63

Notes to the Financial Statements

F
(A
B
)

• J
30, 2024

•)

Notes to the Financial Statements

F 12 31 2024

(A 12 31 2024)

I. 12 31 2024 (C 12 31 2024)

(XX) Assets with restricted ownership or right-of-use

Items	As at the end of the period		Types for restriction	Case for restriction	A 12 31 2024			
	Book balance	Carrying amount			B 12 31 2024	C 12 31 2024	12 31 2024	C 12 31 2024
C 12 31 2024				Bank acceptance deposit				B 12 31 2024
	150,009.00	150,009.00	Guarantee	deposit	772,510.54	772,510.54	F 12 31 2024	12 31 2024
	5,000,000.00	5,000,000.00	Guarantee	Performance bond	12,000,000.00	12,000,000.00	F 12 31 2024	12 31 2024
	1,363,135.53	1,363,135.53	Freezing	Foreign Exchange Control Account	1,361,750.73	1,361,750.73	F 12 31 2024	F 12 31 2024 E 12 31 2024 C 12 31 2024 A 12 31 2024
					2,120.75	2,120.75	F 12 31 2024	12 31 2024
					2,000.00	2,000.00	F 12 31 2024	
12 31 2024	208,244,700.00	208,244,700.00	Pledge	Pledged loans	208,244,700.00	208,244,700.00	12 31 2024	12 31 2024
F 12 31 2024	104,902,010.82	104,902,010.82	Mortgage	Sale and leaseback	101,426,794.17	19,972,320.31	F 12 31 2024	12 31 2024
	215,173,758.25	215,173,758.25	Mortgage	Secured borrowings	161,956,152.45	156,403,944.90	F 12 31 2024	12 31 2024
12 31 2024	26,041,873.00	26,041,873.00	Mortgage	Secured borrowings	59,523,539.00	52,511,079.33	F 12 31 2024	12 31 2024
	240,799,717.53	240,799,717.53			281,904,499.27	274,992,040.60		

(XXI) Short-term borrowings

Items	Balance as at the end of the period	B 12 31 2024
12 31 2024	111,000,000.00	125,000,000.00
G 12 31 2024		2,001,700.00
	111,000,000.00	127,001,700.00

Notes to the Financial Statements

F
(A

(C

(XXII) Financial liabilities held for trading

Items	Balance as at the end of the period	B
Eq	12,400,000.00	12,400,000.00

(XXIII) Accounts payable

Items	Balance as at the end of the period	B
-------	-------------------------------------	---

Notes to the Financial Statements

F 30, 2024
 (A B)

(C)

(XXVI) Employee benefits payable (Continued)

3.

Items	B -	Increase in the current period	Decrease in the current period	Balance as at the end of the period
B	4,113,499.45	17,853,475.62	19,109,187.58	2,862,787.49
	141,199.04	593,688.95	648,098.81	86,789.18
	4,259,698.49	18,447,164.57	19,757,286.39	2,949,576.67

C G

(XXVII) Taxes payable

Items	Balance as at the end of the period	B -
(A)	2,694,016.67	3,056,261.74
E	22,926,288.67	30,600,774.99
	1,720,787.95	1,143,039.23
C	104,506.51	134,739.29
	3,012,925.99	2,960,159.04
E	74,789.97	96,590.13
	305,640.50	523,433.13
	13,843.13	31,053.22
E	2,094.00	1,369.00
F	552.42	771.60
	30,855,445.81	33,553,746.47



Notes to the Financial Statements

Financial statements for the period ending June 30, 2024

(Amounts in thousands of RMB)

1. Other payables (CNY)

(XXVIII) Other payables

Items	Balance as at the end of the period	Balance as at the end of the period
Accounts payable		35,313.43
Other payables	2,370,000.00	624,000.00
	66,117,137.05	149,611,261.72
	68,487,137.05	150,270,575.15

1. Accounts payable

Items	Balance as at the end of the period	Balance as at the end of the period
Accounts payable		35,313.43
		35,313.43

2. Other payables

Items	Balance as at the end of the period	Balance as at the end of the period
Other payables	2,370,000.00	624,000.00
	2,370,000.00	624,000.00

Notes to the Financial Statements

June 30, 2024

(A) (B) (C)

(C)

(XXVIII) Other payables (Continued)

3.

Items	Balance as at the end of the period	B
	17,785,659.46	62,637,634.31
	1,313,457.77	1,313,457.77
	1,740,116.45	6,766,360.73
D	1,237,034.24	1,663,762.95
C	29,986,754.10	33,542,529.94
	3,677,029.66	9,345,641.23
A	8,254,225.35	23,431,495.22
	2,122,860.02	360,379.52
	66,117,137.05	149,611,261.72

(XXIX) Non-current liabilities due within one year

Items	Balance as at the end of the period	B
	44,136,233.34	130,020,000.00
	41,370,743.00	41,747,363.00
	22,779,404.91	23,643,333.99
	108,286,381.25	250,411,500.00

Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in thousands of RMB)

1. Other current liabilities (CNY)

(XXX) Other current liabilities

Items	Balance as at the end of the period	B RMB
Accounts payable	5,575.47	
Prepaid expenses	563,849.74	
	569,425.21	

(XXXI) Long-term borrowings

Items	Balance as at the end of the period	B RMB
Bank loans	89,166,233.34	212,842,127.25
Guaranteed bank loans	306,620,000.00	252,010,000.00
Guaranteed bank loans	416,574,669.65	272,887,087.44
Other long-term borrowings	44,136,233.34	180,020,000.00
	768,224,669.65	557,719,214.69

(XXXII) Lease liabilities

Items	Balance as at the end of the period	B RMB
Lease liabilities	158,912,952.10	163,239,532.76
	158,912,952.10	163,239,532.76

Notes to the Financial Statements

F 30, 2024
 (A B)

(C)

(XXXIII) Long-term accounts payable

Items	Balance as at the end of the period	B
	64,227,913.88	61,351,340.53
	64,227,913.88	61,351,340.53

Items	Balance as at the end of the period	B
	105,598,656.88	103,099,205.53
	15,254,200.16	15,109,210.13
	41,370,743.00	41,747,368.00
	64,227,913.88	61,351,340.53

(XXXIV) Deferred income

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	8,734,099.00		151,896.00	8,582,203.00
	8,734,099.00		151,896.00	8,582,203.00

(XXXV) Share capital

Items	B	Increase (+) decrease (-) in the current period				Subtotal	Balance as at the end of the period
		Issuance of new shares	Bonus issue	conversion from reserves	others		
	74,600,300.00					74,600,300.00	



Notes to the Financial Statements

For the period ended June 30, 2024

(A) (B) (C)

(XXXVI) Capital surplus

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	781,037,804.26		12,709,794.63	768,328,009.63
元	44,857,374.20	767,673.68		45,625,047.88
元	26,800,423.23			26,800,423.23
	852,695,601.69	767,673.68	12,709,794.63	840,753,480.74

(XXXVII) Treasury stock

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
C	12,587,011.74		9,440,179.03	3,146,832.71
元	12,587,011.74		9,440,179.03	3,146,832.71

(XXXVIII) Surplus reserve

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	38,399,577.13			38,399,577.13
	38,399,577.13			38,399,577.13

Notes to the Financial Statements

F
(A

(C

(XXXIX) Retained earnings

Items	Amount for the current period	A
	311,956,229.16	233,506,534.43
A	311,956,229.16	233,506,534.43
A	50,723,744.20	35,947,306.64
A	22,380,090.00	7,493,111.91
D	340,299,883.36	311,956,229.16

(XL) Revenue and cost of sales

1. A

Items	Amount for the current period		A	C
	Revenue	Cost		
	765,636,198.08	555,217,793.42	723,692,633.43	547,491,901.17
	63,321,355.63	47,582,667.69	49,232,530.41	23,393,694.59
	828,957,553.71	602,800,461.11	777,925,163.84	576,390,595.76



Notes to the Financial Statements

For the period ended June 30, 2024

(A company incorporated in the People's Republic of China)

1. Revenue and cost of sales (Continued)

(XL) Revenue and cost of sales (Continued)

1. A company incorporated in the People's Republic of China (Continued)

B. Revenue and cost of sales:

Items	Amount for the current period	A company incorporated in the People's Republic of China
Revenue	765,636,198.08	728,692,633.43
Cost of sales	765,636,198.08	728,692,633.43
Revenue from operations	63,321,355.63	49,232,530.41
Cost of sales from operations	41,715,643.36	28,881,807.57
Revenue from other operations	7,958,001.19	1,485,148.50
Cost of sales from other operations	297,619.53	2,857,971.77
	13,350,091.55	16,007,602.57
	828,957,553.71	777,925,163.84

2. D. Revenue and cost of sales (Continued)

Items	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
Revenue from operations	A company incorporated in the People's Republic of China	B. Revenue and cost of sales	D. Revenue and cost of sales			

Notes to the Financial Statements

F 1 1 2024
 (A 1 1 2024)

1. 1 1 2024 (C 1 1 2024)

(XLI) Taxes and charges

Items	Amount for the current period	A 1 1
	4,886,926.23	1,704,919.27
C 1 1 1 1 1 1	460,954.07	393,619.06
E 1 1 1 1 1	331,720.92	234,361.36
1 1	445,099.29	244,223.99
	130,348.60	139,457.31
	13,249.84	11,774.66
	6,268,298.95	2,733,361.65

(XLII) Selling and distribution expenses

Items	Amount for the current period	A 1 1
E 1 1	5,264,561.40	4,571,354.43
D 1 1 1	99,249.43	96,371.30
A 1 1 1 1	21,787.27	22,513.69
A 1 1 1 1 1 1	155,095.54	155,131.63
E 1 1 1	435,531.57	316,393.31
1 1 1	316,961.17	130,167.93
1 1 1	179,730.55	167,234.65
1 1 1 1		10,473.13
1 1 1 1	219,294.83	235,341.00
1 1 1 1 1 1	2,388,776.86	2,020,072.51
1 1 1 1 1 1 1	139,038.00	25,263.40
	29,239.82	27,732.42
	9,249,266.44	7,323,610.00

Notes to the Financial Statements

F 2024 6 30, 2024

(A 2024 6 30)

1. (C)

(XLIII) General and administrative expenses

Items	Amount for the current period	A
E	63,615,210.18	55,921,762.53
D	7,553,031.91	6,990,039.75
A	1,874,457.13	1,300,111.04
A	4,527,100.72	4,634,159.30
,	963,471.75	1,039,347.77
H	1,323,759.68	1,336,037.33
E	767,673.68	
	2,276,602.65	1,700,201.12
	2,198,731.91	2,070,523.66
	351,396.86	717,753.37
,	2,919,344.90	1,676,255.06
C	1,024,421.20	1,263,793.76
	1,308,692.84	1,532,961.73
C	1,815,859.33	14,377,209.14
A	2,226,500.13	
	5,421,178.66	3,243,243.19
E	2,803,324.36	2,599,553.04
	3,300,625.81	366,013.32
	106,271,383.70	101,924,026.76

(XLIV) Research and development expenses

Items	Amount for the current period	A
E	17,015,841.55	13,993,396.69
D	313,121.72	191,563.31
,	23,806.46	92,076.43
	1,279.22	1,369.72
	7,292.41	333,933.66
	7,536.00	
	219,198.79	235,100.27
	17,588,076.15	14,957,995.63

Notes to the Financial Statements

F 30, 2024
 (A B)

(C)

(XLV) Financial expenses

Items	Amount for the current period	A
	23,323,466.98	19,132,137.46
	5,245,075.86	5,053,106.16
	2,686,209.46	2,704,331.09
	99,244.67	-13,070.04
	3,728,948.96	3,695,397.63
	24,465,451.15	20,159,633.96

(XLVI) Other income

Items	Amount for the current period	A
	5,386,176.18	5,600,421.10
	13,945.83	200,405.44
	188,141.27	21,663.61
	5,588,263.28	5,822,495.15

(XLVII) Investment income

Items	Amount for the current period	A
	478,827.96	-157,522.45
	1,201,371.61	-33,203.43
	1,680,199.57	-195,725.93



Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in thousands of RMB)

1. Gain from change in fair value (Continued)

(XLVIII) Gain from change in fair value

Source of gains from changes in fair value	Amount for the current period	Amount at the beginning of the period
Equity instruments	248,879.60	
Derivatives	-347,402.79	
	-98,523.19	

(XLIX) Credit impairment losses

Items	Amount for the current period	Amount at the beginning of the period
-------	-------------------------------	---------------------------------------

Notes to the Financial Statements

F 2024 6 30

(A B)

1. (C)

(LIII) Income tax expenses

1. 1

Items	Amount for the current period	A
C	19,082,552.41	23,353,206.57
D	-2,566,409.06	-11,330,326.50
	16,516,143.35	11,477,330.07

2. 2

Items	Amount for the current period
	61,512,576.64
	12,647,013.90
	474,180.04
A	-769,492.74
	817,638.14
	-4,610,218.14
	9,615,739.59
	-3,065,849.16
	1,407,131.72
	16,516,143.35

Notes to the Financial Statements

F
(A)

(C)

(LIV) Earnings per share

1. B

B
C

Items	Amount for the current period	A
C	50,723,744.20	43,750,057.46
A	74,600,300.00	74,600,300.00
B	0.68	0.59
B	0.68	0.59

2. D

D
C

Items	Amount for the current period	A
C	50,723,744.20	43,750,057.46
A	74,600,300.00	74,600,300.00
D	0.68	0.59
D	0.68	0.59



Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in RMB)

1. Supplementary information to the cash flow statement (Continued)

(LV) Supplementary information to the cash flow statement

1. Cash flow information

Supplementary information	Amount for the current period	Amount for the prior period
1. Cash flow information		
Cash flow from operating activities	44,996,433.29	43,750,057.46
Cash flow from investing activities		
Cash flow from financing activities		
Net increase (decrease) in cash and cash equivalents		
Cash and cash equivalents at the beginning of the period		
Cash and cash equivalents at the end of the period		



Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024

(All amounts are in RMB million unless otherwise specified)

(I) Disposal of subsidiaries

Name of subsidiary	Disposal price at the date of loss of control	Percentage of disposals at the date of loss of control (%)	Disposal at the date of loss of control	Date of loss of control	Basis for determining the date of loss of control	Difference between the consideration for disposal and the share of net assets of the subsidiary at the level of the relevant consolidated financial statements as of the date of consolidated loss of control
1. Wenzhou Kangning Hospital Co., Ltd.					66% date of loss of control	66% date of consolidated loss of control



Notes to the Financial Statements

Financial statements for the period ending June 30, 2024

(All figures are in RMB unless otherwise specified)

1. Interests in subsidiaries (Continued)

(I) Interests in subsidiaries (Continued)

2. **Wenzhou Kangning Hospital Co., Ltd.**

Name of Subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
Wenzhou Kangning Hospital Co., Ltd.	40.00%	44,636.00		30,411,626.36
Wenzhou Kangning Hospital Co., Ltd.	45.00%	-1,622,191.24		16,064,103.54

3. **Wenzhou Kangning Hospital Co., Ltd.**

Name of Subsidiary	Balance as at the end of the period						Balance as at the end of the period		
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities	Current assets	Non-current assets	Total assets
Wenzhou Kangning Hospital Co., Ltd.	8,793,123.17	162,275,430.25	171,068,553.42	39,487.47	95,000,000.00	95,039,487.47	12,771,926.28	126,317,515.02	139,089,441.30
Wenzhou Kangning Hospital Co., Ltd.	8,951,720.53	70,164,028.21	79,115,748.74	14,151,720.45	28,010,857.21	42,162,577.66	13,868,975.32	71,012,513.90	84,881,489.22

Name of Subsidiary	Amount for the current period				Amount for the current period		
	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities	Revenue	Net profit	Total comprehensive income
Wenzhou Kangning Hospital Co., Ltd.		111,715.00	111,715.00	7,479,658.56	-1,000,974.74	-1,000,974.74	-3,869,458.16
Wenzhou Kangning Hospital Co., Ltd.	9,111,507.81	-3,604,869.42	-3,604,869.42	-2,290,977.91	16,050,977.70	-2,862,161.57	-2,862,161.57

Notes to the Financial Statements

F 2024

(A B)

I. (C)

(II) Transactions that cause changes in the share of owners' equity in subsidiaries that do not result in loss of control

1. E 2024, B H C B A B0.3 B1 B15,300,000.00 B46,536,700.00, C 51% 67.7%.

A B3,375,411.44, ()

(III) Interests in joint arrangements or associates

1. B B

Name of joint venture or associate	Major business location	Place of registration	Nature of business	Shareholding (%)		Accounting method for investment in joint ventures or associates	Whether strategic to the Company's activities or not
				Direct	Indirect		
H C				45.00		E	y
H C			H		30.00	E	y

Notes to the Financial Statements

F 2024 10 31

(A 2024 10 31)

1. 2024 10 31 (C 2024 10 31)

(III) Interests in joint arrangements or associates (Continued)

2. 2024 10 31 2023 10 31

	Closing balance/amount for the current period		Closing balance/amount for the prior period	
	Wenzhou Longwan Yining Hospital Co., Ltd.	Shaanxi Shanda Hospital Management Consulting Co., Ltd.	2024 10 31 C 2024 10 31	2023 10 31 C 2023 10 31
C 2024 10 31	5,919,113.19	44,911,330.78	46,656,767.88	71,300,257.36
2023 10 31	192,825,147.06	112,258,865.02	152,199,429.22	117,230,334.02
	198,744,260.25	157,170,195.80	198,856,197.10	188,530,591.38
C 2024 10 31	37,799,777.29	80,049,646.18	37,541,901.86	97,460,588.12
2023 10 31	35,000,000.00	454,341.99	35,000,000.00	15,000,000.00
2024 10 31	72,799,777.29	80,503,988.17	72,541,901.86	112,460,588.12
2023 10 31		17,565,753.51		19,343,974.26
E 2024 10 31	125,944,482.96	59,100,454.12	126,314,295.24	56,726,029.00
2023 10 31	56,675,017.33	22,999,862.29	56,841,432.86	22,821,000.98
A 2024 10 31				
G 2024 10 31				
2023 10 31				
C 2024 10 31				
F 2024 10 31				
2023 10 31				
2024 10 31		45,293,374.09		47,654,671.86
2023 10 31	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
2024 10 31				
2023 10 31				
2024 10 31	-369,812.28	2,374,425.12	-257,993.98	1,052,984.93
D 2024 10 31				

Notes to the Financial Statements

F
(A

II. (C

(I) Various risks associated with financial instruments (Continued)

2. (C

C

Items	Closing balance					Total undiscouted contract amount	Book value
	Instant repayment	Within 1 year	1-2 years	2-5 years	Over 5 years		
		112,544,938.03				112,544,938.03	112,544,938.03
		68,487,137.05				68,487,137.05	68,487,137.05
		111,000,000.00				111,000,000.00	111,000,000.00
		108,286,381.25				108,286,381.25	108,286,381.25
			287,545,000.00	314,094,120.00	166,585,549.65	768,224,669.65	768,224,669.65
			18,133,866.38	54,983,512.27	95,622,594.14	168,739,972.79	158,912,952.10
				25,945,947.15	45,352,431.95	71,298,379.10	64,227,913.88
		400,318,456.33	331,624,813.53	414,430,064.22	262,208,143.79	1,408,581,477.87	1,210,651,916.88

B

10,143.7324 0 3,023 5 227.56 3

Notes to the Financial Statements

F 2024 12 31

(A B C)

III. D (C)

(II) Qualitative and quantitative information of valuation techniques and key parameters adopted for items measured at the fair value of level 3 on a going and non-going concern

1. 2024 12 31 2023 12 31

2. 2024 12 31 2023 12 31

C H

A C

Notes to the Financial Statements

For the period ended June 30, 2024

(A subsidiary of B Company)

1. Information of other related parties (Continued)

(IV) Information of other related parties

Name of other related parties	Other related parties' relationship with the Company
C Company	Director
C Company G	Director
J Company D	Director
Company B, Company A	Director
(寧波梅山保稅港區寬展投資管理合夥企業(有限合伙))	Director
Company F, Company H, Company C	Director
Company H	Director
Company	Director
Company	Director
Company	Director
Company H, Company C	Director
(四川省宏濟藥業有限責任公司)	Director
Company C	Director
Company H, Company C	Director
Company E, Company C	Director
Company y, Company C	Director
Company H, Company C	Director
Company A, Company C	Director
Company H, Company C	Director

Notes to the Financial Statements

F
(A)

(C)

(V) Information on related party transactions

1.

Related party	Amount for the period	A
F	46,490.62	
A	17,960.18	

Related party	Amount for the period	A
H	1,485,148.52	1,485,148.50
H	84,905.66	

Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in RMB Yuan)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Information on bank guarantees provided by the Company:

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
温州市人民医院有限公司	14,660,000.00	2019/9/10	2029/9/20	是
温州市人民医院有限公司	10,290,000.00	2020/1/1	2029/9/20	是
温州市人民医院有限公司	3,320,000.00	2020/12/22	2029/9/20	是
温州市人民医院有限公司	2,200,000.00	2020/9/27	2029/9/20	是
温州市人民医院有限公司	2,200,000.00	2020/9/27	2029/9/20	是
温州市人民医院有限公司	3,050,000.00	2021/3/1	2029/9/20	是
温州市人民医院有限公司	3,050,000.00	2021/3/1	2029/9/20	是
温州市人民医院有限公司	45,000,000.00	2023/7/3	2037/12/31	是
温州市人民医院有限公司	15,000,000.00	2023/7/31	2037/12/31	是
温州市人民医院有限公司	10,116,550.00	2023/10/25	2037/12/31	是
温州市人民医院有限公司	5,007,200.00	2023/11/24	2037/12/31	是
温州市人民医院有限公司	5,000,000.00	2020/3/25	2024/12/20	是
温州市人民医院有限公司	17,500,000.00	2020/5/22	2024/12/20	是
温州市人民医院有限公司	60,000,000.00	2023/10/9	2031/10/9	是
温州市人民医院有限公司	2,000,000.00	2023/3/31	2024/3/29	是
温州市人民医院有限公司	26,000,000.00	2023/4/3	2032/3/2	是

Notes to the Financial Statements

For the year ended December 31, 2024

(All amounts are in US dollars unless otherwise indicated)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Guarantees provided (Continued)

The following table summarizes the guarantees provided:

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
Yantai Zhongyuan Chemical Co., Ltd.	200,000,000.00		2026/12/24	Yes
Yantai Zhongyuan Chemical Co., Ltd.	200,000,000.00		2026/12/24	Yes
Yantai Zhongyuan Chemical Co., Ltd.	200,000,000.00		2026/12/24	Yes
Yantai Zhongyuan Chemical Co., Ltd.	66,474,000.00		2026/12/10	Yes
Yantai Zhongyuan Chemical Co., Ltd.	200,000,000.00		2026/12/24	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	24,000,000.00	2020/6/30	2027/6/30	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	79,642,127.25	2021/11/29	2025/11/29	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	130,950,000.00	2020/10/26	2026/10/25	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	70,000,000.00	2023/11/3	2026/11/15	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	135,000,000.00	2023/12/14	2024/12/14	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	14,660,000.00	2019/9/10	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	10,230,000.00	2020/1/1	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	3,320,000.00	2020/12/22	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	2,200,000.00	2020/9/27	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	2,200,000.00	2020/9/27	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	3,050,000.00	2021/3/1	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	3,050,000.00	2021/3/1	2029/9/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	45,000,000.00	2023/7/3	2037/12/31	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	15,000,000.00	2023/7/31	2037/12/31	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	10,116,550.00	2023/10/25	2037/12/31	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	5,007,200.00	2023/11/24	2037/12/31	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	5,000,000.00	2020/3/25	2024/12/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.	17,500,000.00	2020/5/22	2024/12/20	Yes
Guangdong Zhongyuan Chemical Co., Ltd.				Yes
Guangdong Zhongyuan Chemical Co., Ltd.	60,000,000.00	2023/10/9	2031/10/9	Yes

Notes to the Financial Statements

F 1 1 1 • J 30, 2024

(A 1 1 B 1 1)

I . • 1 1 • 1 1 (C 1 1)

(VI) Receivables from and payables to related parties and other unsettled items

1. 1 1

Items	Related parties	Balance as at the end of the period		B 1 1	
		Book balance	Provision for bad debts	B 1 1	1 1
A 1 1 1 1	H 1 1 y 1 1 1			65,000.00	3,250.00
	H 1 1 C 1 1 1 1				
	H 1 1 A 1 1 1 1				
	C 1 1 1 1	1,522.85	15.23	1,522.85	15.23
	H 1 1 1 1	635,000.00	6,350.00	635,000.00	6,350.00
1 1	H 1 1 y 1 1 1	23,066,977.13	23,066,977.13	34,005,471.02	1,700,273.55
	H 1 1 C 1 1 1 1				
	C 1 1 1 1	13,903,890.41	695,194.52	14,290,027.40	714,501.37
	C 1 1 1 1	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	C 1 1 1 1	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	C 1 1 1 1	16,836.66	841.83	16,836.66	841.83
	C 1 1 G 1 1 1 1	100,000.00	1,000.00	100,000.00	1,000.00
	1 1	80,004.00	800.04	80,004.00	800.04
	C 1 1 1 1	75,187.50	3,759.38	105,187.50	5,259.38
	J 1 1 D 1 1 1 1	431,587.50	21,579.38	479,707.50	23,985.38



Notes to the Financial Statements

附注 截至 2024 年 6 月 30 日

(续前表)

1. 关联方往来款项 (续前表)

(VI) 关联方往来款项和其他未结事项 (Continued)

2.

Item	Related parties	Billion RMB	
		Book balance as at the end of the period	
		1.00	1.00

Notes to the Financial Statements

F J- 30, 2024
(A B)

I . (C)

(VII) Five Individuals with Highest Remunerations

F J- J- 2024, J- 2023: 0), A C

Items Amount for Totalble:

Notes to the Financial Statements

F 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
 (A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100)

(I) Summary of share-based payment (Continued)

2023	2022
3,730,015	3,730,015
36	36
616,000	616,000
335,000	335,000
75,000	75,000
1,240,100	1,240,100
1.66%	1.66%

Notes to the Financial Statements

F 2024 12 31

(A B)

(C)

(I) Summary of share-based payment (Continued)

2. H A (C)

100 100 C 100

100 100 C 100

C 100 100 100 100 100 100

100 100 100 100 100 100

48

(II) Equity-settled share-based payment

100 100 100 100 100 100

B 10.57 10.47

100 100 100 100 100 100

100 100 100 100 100 100

100 100 100 100 100 100

A 100 100 100 100 100 100

A J 30, 2024, 100 100 100 100 100 100

100 100 100 100 100 100

100 100 100 100 100 100

Notes to the Financial Statements

F
(A

I. C

(I) Significant commitments

1. C

	June 30, 2024 D	31, 2023
H	55,890,951.92	122,040,000.00
	55,890,951.92	122,040,000.00

2.

A J_{30, 2024}, C

(II) Contingencies

C

II. E

(I) Profit distribution

B • B
2024
C), B1.50 () 10
C

Notes to the Financial Statements

F 2024 10 31

(A B)

III. C

C

C

C

C

C

A

	Balance as at the end of the period	B
D	52.58%	53.79%

I. A

(I) Segment Information

Notes to the Financial Statements

F
(A
B
)
J 30, 2024

(I) Accounts receivable

1. Accounts receivable

Aging	Balance as at the end of the period	B
1	51,071,471.71	43,552,073.47
1-2	11,406,851.48	257,315.13
2-3	257,315.13	709,373.26
3	4,616,400.13	3,906,521.37
-	67,352,038.45	53,425,793.73
••	11,362,291.77	5,359,236.04
	55,989,746.68	43,066,557.69

Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in RMB)

(Continued)

(I) Accounts receivable (Continued)

2. Accounts receivable

Category	Balance as at the end of the period				Carrying amount	Billion RMB		
	Book balance		Provision for bad debts			A	B	C
	Amount	Proportion (%)	Amount	Proportion of provision (%)				
Accounts receivable	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	9.12	4,873,715.26	100.00
Provision for bad debts:								
Provision for specific bad debts	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	9.12	4,873,715.26	100.00
Provision for general bad debts	57,018,962.00	92.76	6,488,576.51	11.38	50,530,385.49	49.88	49,520.79	1.00
Provision for doubtful accounts	5,459,361.19	8.11			5,459,361.19			
Provision for other bad debts	57,018,962.00	84.66	6,488,576.51	11.38	50,530,385.49	49.88	49,520.79	1.00
	67,352,038.45	100.00	11,362,291.77		55,989,746.68	53.42	5,359,236.04	49.88

3. Accounts receivable

Items	Balance as at the end of the period				Reason for the provision	Billion RMB	
	Book balance	Provision for bad debts	Proportion of provision (%)	Carrying amount		B	C
Accounts receivable	4,873,715.26	4,873,715.26	100.00	Not expect to be recoverable	4,873,715.26	4,873,715.26	
	4,873,715.26	4,873,715.26			4,873,715.26	4,873,715.26	

Notes to the Financial Statements

F 30, 2024
 (A B)

(II) Other receivables (Continued)

3. (1) D

Aging	Balance as at the end of the period	B
1	571,062,190.36	552,353,723.97
1 2	5,089,808.65	34,594,797.65
2 3	33,287,580.41	496,167.22
3	1,158,794.57	903,479.96
	610,598,373.99	583,353,173.80
	2,863,290.39	2,304,343.22
	607,735,083.60	585,657,517.02

(2) D

Category	Balance as at the end of the period		Provision for bad debts		Book value	B		B		
	Book balance	Provision for bad debts	Amount	Proportion of provision (%)		A	(%)	A	(%)	
	610,598,373.99	2,863,290.39	2,863,290.39	0.47	607,735,083.60	585,653,173.80	100.00	2,304,343.22	0.4%	585,048,830.58
	80,464,046.88	2,863,290.39	2,863,290.39	3.56	77,600,756.49	75,462,763.59	12.92	2,304,343.22	3.72	72,657,920.37
	530,134,327.11			86.82	530,134,327.11	513,390,405.21				513,390,405.21
	610,598,373.99	2,863,290.39		/	607,735,083.60	585,653,173.80	100.00	2,304,343.22	/	585,048,830.58

Notes to the Financial Statements

For the period ended June 30, 2024

(Amount in RMB)

3. Other receivables (Continued)

(II) Other receivables (Continued)

3. Other receivables (Continued)

(2) Details of other receivables as at the end of the period:

1. Details of other receivables as at the end of the period:

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
Accounts receivable	80,464,046.88	2,863,290.39	3.56
Accounts receivable	530,134,327.11		
	610,598,373.99	2,863,290.39	

Notes to the Financial Statements

F 2024 10 31

(A B C)

(C)

(II) Other receivables (Continued)

3. (C)

(3) D (C)

C :
 12-month ECL Lifetime ECL (not credit impaired) Lifetime ECL (credit impaired)

	Stage I 12-month ECL	Stage II Lifetime ECL (not credit impaired)	Stage III Lifetime ECL (credit impaired)	Total
B				
B	588,853,173.80			588,853,173.80
B				
-				
-				
-				
-				
A	21,745,200.19			21,745,200.19
D				
B	610,598,373.99			610,598,373.99



Notes to the Financial Statements

F 2024 12 31 30, 2024

(A B)

(C)

(III) Long-term equity investments

Items	Balance as at the end of the period			B	
	Book balance	Provision for impairment	Book value	B	B
1	698,830,684.03		698,830,684.03	691,561,513.66	691,561,513.66
1	94,549,945.13		94,549,945.13	94,421,925.51	94,421,925.51

Notes to the Financial Statements

F 30, 2024

(A B)

(C)

(III) Long-term equity investments (Continued)

1. 7 9

Investees	Increase/decrease in the current period				Balance as at the end of the period	Balance of the impairment provision as at the end of the period
	B	Increase in investment	Decrease in investment	Provision for impairment for the current period		
Investees						
• H C . .	15,500,000.00				15,500,000.00	
F J	500,000.00				500,000.00	
C . .	204,666,253.87		43,684.64		204,709,938.51	
C . .	52,697,737.50				52,697,737.50	
Y H C . .	2,133,258.38				2,133,258.38	
Y H C . .	27,687,093.11				27,687,093.11	
H C . .	32,856,644.25				32,856,644.25	
H C . .	4,799,071.39		4,272.04		4,803,343.43	
C . .	53,500,000.00		15,660.04		53,515,660.04	
H C . .	40,800,000.00	7,200,000.00			48,000,000.00	
H C . .	10,000,000.00				10,000,000.00	
C . .	154,744,700.00		5,553.65		154,750,253.65	
C . .	29,051,800.00				29,051,800.00	
H C . .						
H C . .	40,954,955.16				40,954,955.16	
D H C . .	14,510,000.00				14,510,000.00	
C . .	500,000.00				500,000.00	
H C . .	6,660,000.00				6,660,000.00	
	691,561,513.66	7,200,000.00	69,170.37		698,830,684.03	

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024

(Amount in thousands of RMB)

Investees	Balance at the beginning of the period	Increase/decrease in the current period					Balance at the end of the period
		Investment	Investment recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid	
A							
H							
B							
1							
2							
3							
4							
5							
6							
7							
8							
9							
10							
11							
12							
13							
14							
15							
16							
17							
18							
19							
20							
21							
22							
23							
24							
25							
26							
27							
28							
29							
30							
31							
32							
33							
34							
35							
36							
37							
38							
39							
40							
41							
42							
43							
44							
45							
46							
47							
48							
49							
50							
51							
52							
53							
54							
55							
56							
57							
58							
59							
60							
61							
62							
63							
64							
65							
66							
67							
68							
69							
70							
71							
72							
73							
74							
75							
76							
77							
78							
79							
80							
81							
82							
83							
84							
85							
86							
87							
88							
89							
90							
91							
92							
93							
94							
95							
96							
97							
98							
99							
100							
101							
102							
103							
104							
105							
106							
107							
108							
109							
110							
111							
112							
113							
114							
115							
116							
117							
118							
119							
120							
121							
122							
123							
124							
125							
126							
127							
128							
129							
130							
131							
132							
133							
134							
135							
136							
137							
138							
139							
140							
141							
142							
143							
144							
145							
146							
147							
148							
149							
150							
151							
152							
153							
154							
155							
156							
157							
158							
159							
160							
161							
162							
163							
164							
165							
166							
167							
168							
169							
170							
171							
172							
173							
174							
175							
176							
177							
178							
179							
180							
181							
182							
183							
184							
185							
186							
187							
188							
189							
190							
191							
192							
193							
194							
195							
196							
197							
198							
199							
200							
201							
202							
203							
204							
205							
206							
207							
208							
209							
210							
211							
212							
213							
214							
215							
216							
217							
218							
219							
220							
221							
222							
223							
224							
225							
226							
227							
228							
229							
230							
231							
232							
233							
234							
235</							

Notes to the Financial Statements

F 30, 2024

(A B)

(IV) Revenue and cost of sales

1. \square

Items	Amount for the current period		A	
	Revenue	Cost		C
\square	185,247,902.83	130,785,130.41	174,575,542.75	130,785,397.79
\square	7,845,218.13		1,629,256.25	
	193,093,120.96	130,785,130.41	176,204,799.00	130,785,397.79

B :

Items	Amount for the current period	A
\square	185,247,902.83	174,575,542.75
\square	185,247,902.83	174,575,542.75
\square	7,845,218.13	1,629,256.25
\square	6,472,852.67	
\square	209,955.19	512,200.25
	1,162,410.27	1,117,055.97
	193,093,120.96	176,204,799.00

2. D \square \square \square \square

Item	Time to fulfil performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
\square	A \square	\square	D \square	\square	\square	\square

zA ● 1 C 1 ● 1, 1 B ●

zB 1 y 1 H 1 B 1 y 1 H 1 C .. ● (北京怡寧醫院有限公司), 1 1 ● 1
C 1 1 ● 1 1 1 A 17, 2015, 1 C 1 1 1 1

zB ● D 1, 1 zB ● ● 1, 1 C 1

zC 1 1 1 H 1 C 1 1 1 H 1 C .. ● (蒼南康寧醫院有限公司) A 2 1 -
1 1 5 J 1 A.5 () 0.2 (1 A 17, 2015, 9EB 5 6 C 1) J31.952 0.053 ● (') 1-32.174 -1.5 ● (1 2 00)

B 1, 1 D 1, 1

Definitions

zD 1.00 ()



